v3.26.1
Share Based Payment (Tables)
12 Months Ended
Dec. 31, 2025
Share Based Payment [Abstract]  
Schedule of the Total Share-Based Payment Expense

The total share-based payment expense is as follows:

 

2025

 

2024

2021 unvested awards

 

 

2,834

2025:

       

PSUs

 

15

 

Equity-settled RSUs

 

197

 

Compound RSUs

 

24

 

Total

 

236

 

2,834

         

Recognized as an expense (see note 9)

 

235

 

2,834

         

Classified within equity

 

212

 

2,834

Classified as a liability

 

25

 

Total

 

236

 

2,834

Schedule of Performance Stock Units No cash-settlement alternative is available under the terms of the plan for these PSUs.
 

2025

Share units granted:

 

PSUs

Grant Date

 

December 13, 2025

Vesting Date

 

December 6, 2027

Number of units granted

 

323,777

Schedule of Equity-Settled Restricted Share Units The equity-settled share-based expense as at December 31, 2025 relates to non-executive directors and amounted to $197,388.
 

2025

Share units granted:

 

RSUs

Grant Date

 

October 6, 2025

Vesting Date

 

April 1, 2026

Number of units granted

 

124,617

Schedule of Compound Restricted Share Units The expense relating to Compound Restrictive Share Units for the current year amounted to $23,784.
 

2025

Share units granted:

 

RSUs

Grant Date

 

December 6, 2025

Vesting Date

 

50%: December 6, 2026
50%: December 6, 2027

Number of units granted

 

323,777

Schedule of the Information Required by IFRS 2 for the PSUs, Equity-Settled RSUs and the Compound RSUs

This table summarizes additional information for the PSUs, equity-settled RSUs and the compound RSUs:

December 31, 2025

 

PSUs

 

Equity-settled
RSUs

 

Compound RSUs

Vesting Period

 

2 Years

 

6 months

 

2 Years

Maximum term of options

 

2 years

 

6 Months

 

2 Years

Method of settlement

 

Equity

 

Equity

 

Choice of equity or cashless basis (investment in an approved investment fund)

Classification

 

Equity-settled

 

Equity-settled

 

Compound: equity-settled and cash-settled

Reconciliation:

           

Outstanding at beginning of the period

 

 

 

Granted during the period

 

323,777

 

124,617

 

323,777

Forfeited during the period

 

 

 

Expired during the period

 

 

 

Outstanding at end of the period

 

323,777

 

124,617

 

323,777

Weighted average exercise price

 

 

 

Weighted average remaining contractual life

 

23 months

 

3 Months

 

17 Months